EPO Patents = 5

Forward Citations = 3

Loading Chart...

10 inventors (with patents filed for the assignee):

Jean-Marc Le Doussal (6 out of 8 patents)

Mylene Dorvillius (5 out of 5 patents)

Mickael Terme (4 out of 4 patents)

4. Denis Cochonneau (3 out of 3 patents)

5. Stephane Birkle (2 out of 3 patents)

6. Brigitte Assouline (2 out of 6 patents)

7. Mickaël Terme (2 out of 2 patents)

8. Stéphane Birkle (1 out of 2 patents)

9. Sébastien Faraj (1 out of 1 patent)

10. Julien Fleurence (1 out of 1 patent)

11. Jean-Marc Le Doussal (0 patent)

12. Mylène Dorvillius (0 patent)

6 patents: Sort by Forward Citations

1. 11697689 - Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs (2023-07-11),

2. 11440968 - Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2) (2022-09-13),

3. 10745489 - Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy forcancer (2020-08-18),

4. 10669328 - Human IgG1 derived antibody with pro-apoptotic activity (2020-06-02),

5. 10611848 - Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity (2020-04-07),

6. 10000575 - Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer (2018-06-19),

Company Overview

Ogd2 Pharma is a leading pharmaceutical company specializing in the development and manufacturing of innovative medicines. With a focus on research and development, Ogd2 Pharma is committed to providing high-quality, effective, and affordable pharmaceutical solutions for patients around the world.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#16 in Nantes

#2,488 in France

Nantes, France

Ogd2 Pharma

Forward Citations = 3

10 inventors:

Jean-Marc Le Doussal (6 out of 8 patents)

Mylene Dorvillius (5 out of 5 patents)

Mickael Terme (4 out of 4 patents)

4. Denis Cochonneau (3 out of 3 patents)

5. Stephane Birkle (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ogd2 Pharma. Retrieved from https://idiyas.com/company/ogd2-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

5 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]